- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT03729791
The Effect of tDCS on Schizophrenia With Negative Symptoms
Clinical Trials for Neuroimaging and Electrophysiology in Schizophrenic Patients With Negative Symptoms Using Transcranial Direct Current Stimulation
Studie Overzicht
Gedetailleerde beschrijving
The project will investigate the use of a novel technique, transcranial direct current stimulation (tDCS) in the treatment of patients with schizophrenia. tDCS permit the application of an extremely weak continuous electrical current to the brain through an anode and a cathode applied on the scalp. Anodal stimulation appears to increase brain activity whereas cathodal stimulation has the opposite effect.
Using anodal and cathodal tDCS the investigators aimed to treat negative symptoms of schizophrenia. The investigators plan to apply tDCS such that it can simultaneously increased activity in the frontal brain areas and reduce activity over temporoparietal cortex, 2 areas involved in the physiopathology of the disease. Real active stimulation will be compare to a sham condition in 44 patients (22 in each group). 44 patients will be included in Seoul National University Hospital
Studietype
Inschrijving (Verwacht)
Fase
- Niet toepasbaar
Contacten en locaties
Studiecontact
- Naam: Tae Young Lee, MD
- Telefoonnummer: 82236687663
- E-mail: leetaey@gmail.com
Studie Locaties
-
-
-
Seoul, Korea, republiek van
- Seoul National University Hospital
-
Contact:
- Tae Young Lee, MD
- Telefoonnummer: 82236687663
- E-mail: leetaey@gmail.com
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- DSM-IV Schizophrenia
- 1 or more items of Negative symptom score in PANSS > 5
Exclusion Criteria:
- presences of neurological disorder or history
- IQ < 70
- presence of severe personality disorders
- presence of substance use disorder (except nicotin)
- pregnancy
- presence of severe medical condition or disorders
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Verviervoudigen
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
---|---|
Experimenteel: actual tDCS
2mA direct current, 20 minutes per session, 2 sessions per day with at least 3hours interval between sessions, a total of 10 tDCS sessions
|
Transcranial direct current stimulation (tDCS) is a form of neurostimulation that uses constant, low direct current delivered via electrodes on the head.
It can be contrasted with cranial electrotherapy stimulation, which generally uses alternating current the same way
|
Actieve vergelijker: sham tDCS
sham direct current, 20 minutes per session, 2 sessions per day with at least 3hours interval between sessions, a total of 10 tDCS sessions
|
Transcranial direct current stimulation (tDCS) is a form of neurostimulation that uses constant, low direct current delivered via electrodes on the head.
It can be contrasted with cranial electrotherapy stimulation, which generally uses alternating current the same way
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Positive and Negative Syndrome Scale (PANSS)
Tijdsspanne: approximately 2 weeks (baseline and 2 weeks followups)
|
changes in psychopathology To assess a patient using PANSS, an approximately 45-minute clinical interview is conducted.
The patient is rated from 1 to 7 on 30 different symptoms based on the interview as well as reports of family members or primary care hospital workers
|
approximately 2 weeks (baseline and 2 weeks followups)
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
The Clinical Assessment Interview for Negative Symptoms (CAINS)
Tijdsspanne: approximately 2 weeks (baseline and 2 weeks followups)
|
changes in psychopathology The CAINS is a clinical rating scale for negative symptoms with potent and clear treatment targets for the next generation of pharmacological and psychosocial treatments.
It rangs between 0 to 52
|
approximately 2 weeks (baseline and 2 weeks followups)
|
Electroencephalography - resting
Tijdsspanne: approximately 2 weeks (baseline and 2 weeks followups)
|
changes in lagged phase synchronization and microstate connectivity
|
approximately 2 weeks (baseline and 2 weeks followups)
|
Electroencephalography - P300
Tijdsspanne: approximately 2 weeks (baseline and 2 weeks followups)
|
changes in P300
|
approximately 2 weeks (baseline and 2 weeks followups)
|
Electroencephalography - MMN
Tijdsspanne: approximately 2 weeks (baseline and 2 weeks followups)
|
changes in MMN
|
approximately 2 weeks (baseline and 2 weeks followups)
|
Electroencephalography - ERN
Tijdsspanne: approximately 2 weeks (baseline and 2 weeks followups)
|
changes in ERN
|
approximately 2 weeks (baseline and 2 weeks followups)
|
MRI - grey matter volume
Tijdsspanne: approximately 2 weeks (baseline and 2 weeks followups)
|
change in grey matter volume
|
approximately 2 weeks (baseline and 2 weeks followups)
|
MRI - cortical thickness
Tijdsspanne: approximately 2 weeks (baseline and 2 weeks followups)
|
change in cortical thickness
|
approximately 2 weeks (baseline and 2 weeks followups)
|
MRI - cortical surface area
Tijdsspanne: approximately 2 weeks (baseline and 2 weeks followups)
|
changes in MRI - cortical thickness
|
approximately 2 weeks (baseline and 2 weeks followups)
|
MRI - cortical gyrification
Tijdsspanne: approximately 2 weeks (baseline and 2 weeks followups)
|
changes in cortical gyrification
|
approximately 2 weeks (baseline and 2 weeks followups)
|
DTI - mean diffusivity (MD)
Tijdsspanne: approximately 2 weeks (baseline and 2 weeks followups)
|
changes in MD
|
approximately 2 weeks (baseline and 2 weeks followups)
|
DTI - axial diffusivity (AD)
Tijdsspanne: approximately 2 weeks (baseline and 2 weeks followups)
|
changes in AD
|
approximately 2 weeks (baseline and 2 weeks followups)
|
DTI - radial diffusivity (RD)
Tijdsspanne: approximately 2 weeks (baseline and 2 weeks followups)
|
changes in RD
|
approximately 2 weeks (baseline and 2 weeks followups)
|
DTI - fractional anisotropy (FA)
Tijdsspanne: approximately 2 weeks (baseline and 2 weeks followups)
|
changes in FA
|
approximately 2 weeks (baseline and 2 weeks followups)
|
MRI - rsfMRI
Tijdsspanne: approximately 2 weeks (baseline and 2 weeks followups)
|
change in BOLD signals
|
approximately 2 weeks (baseline and 2 weeks followups)
|
MRI - MRS
Tijdsspanne: approximately 2 weeks (baseline and 2 weeks followups)
|
Changes in concentration of N-Acetyl Aspartate, Creatin, Choline, Myoinositol, Glutamate, Glutamine, GABA metabolite concentration change with treatment
|
approximately 2 weeks (baseline and 2 weeks followups)
|
fNIRS
Tijdsspanne: approximately 2 weeks (baseline and 2 weeks followups)
|
change in level of the Oxy-Hemoglobin
|
approximately 2 weeks (baseline and 2 weeks followups)
|
Korean Wechsler Adult Intelligence Scale (K-WAIS)
Tijdsspanne: baseline
|
baseline total Intelligence quotient value
|
baseline
|
Spatial Working Memory
Tijdsspanne: approximately 2 weeks (baseline and 2 weeks followups)
|
changes in the spatial working memory ability
|
approximately 2 weeks (baseline and 2 weeks followups)
|
California Verbal Learning Test
Tijdsspanne: approximately 2 weeks (baseline and 2 weeks followups)
|
changes in verbal learning ability
|
approximately 2 weeks (baseline and 2 weeks followups)
|
Letter/Category fluency test
Tijdsspanne: approximately 2 weeks (baseline and 2 weeks followups)
|
changes in fluency ability
|
approximately 2 weeks (baseline and 2 weeks followups)
|
Medewerkers en onderzoekers
Onderzoekers
- Hoofdonderzoeker: Tae Young Lee, MD, Seoul National University Hospital
Studie record data
Bestudeer belangrijke data
Studie start (Verwacht)
Primaire voltooiing (Verwacht)
Studie voltooiing (Verwacht)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- 1.001
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
product vervaardigd in en geëxporteerd uit de V.S.
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op tDCS
-
Hôpital le VinatierVoltooidSchizofrenie | Auditieve hallucinatiesFrankrijk, Tunesië
-
Universidad de AlmeriaSecretaría General de Universidades, Investigación y Tecnología, Junta de Andalucía...Aanmelden op uitnodigingMiddelgerelateerde aandoeningenSpanje
-
Northeastern UniversityMassachusetts General Hospital; National Institute on Aging (NIA)Onbekend
-
Bambino Gesù Hospital and Research InstituteVoltooid
-
University of ArizonaWervingPrimaire progressieve afasieVerenigde Staten
-
University of North Carolina, Chapel HillNational Institute of Mental Health (NIMH)VoltooidMotorische activiteit | Motorische neuroplasticiteitVerenigde Staten
-
Charite University, Berlin, GermanyVoltooidMigraine Met Aura | CADASIL | Cerebrale microangiopathie | ICA-stenoseDuitsland
-
Universidade Federal de PernambucoVoltooid
-
New York UniversityWervingGezondVerenigde Staten
-
University of MichiganNational Institute of Mental Health (NIMH)Voltooid